PharmaTher Holdings Ltd
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Fabio Chianelli
- Full Time Employees
- 8
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 82 Richmond Street East Toronto ON Canada M5C 1P1
- IPO Date
- Oct 9, 2020
- Website
- pharmather.com
- Similar Companies
- Business
- PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company focused on the research, development, and commercialization of ketamine-based therapies for mental health, neurological, pain, and medical countermeasures indications. Founded in 2020 and headquartered in Toronto, Ontario, the company offers KETARX (racemic ketamine injection) for anesthesia, sedation, and treatment-resistant depression; KET-100, a patented long-acting injectable ketamine formulation for neuropsychiatric disorders; ketamine transdermal microneedle patches and wearable pumps for non-opioid pain relief; KETABET for potential rare disease applications; and the proprietary KetAImine platform for ketamine repurposing, indication discovery, and combination therapies via the FDA 505(b)(2) pathway; it additionally holds license agreements with BioRAE Inc. for gelatin methacryloyl microneedles, the University of Kansas for ketamine in ALS, and Queen's University of Belfast for hydrogel microneedle technology, while owning 49% of Sairiyo Therapeutics Inc. PharmaTher operates primarily in Canada with global ambitions, targeting hospitals, specialty clinics, government institutions, and clinical research customers. Recent developments include the December 2025 closing of the sale of its Ketamine Hydrochloride Injection USP ANDA (#217858) to a leading global sterile injectables manufacturer, providing non-dilutive capital tied to U.S. sales royalties and enabling focus on proprietary long-acting injectables; advancement of ketamine transdermal patches post-FDA approval of IV ketamine; launch of the KetAImine discovery platform in October 2025; and strategic pursuits of international partnerships, FDA engagements for complex regional pain syndrome and Parkinson's disease programs, and pharmaceutical collaborations for microneedle and pump technologies.
Company News
PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES
PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform
PharmaTher Holdings Ltd. (OTCMKTS:PHRRF) Shares Shorted: Short Interest Up 98.5% in September
PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing
PharmaTher Collaborates with Craft Health to Evaluate CraftMake(TM) GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptides
PharmaTher Launches Personaliz3D Peptides(TM) to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations
PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval
PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics
PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines
PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness
PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides
PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery
PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology
PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches
PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market
PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success
PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs
PharmaTher CEO Publishes Letter to Shareholders